Comparison of right ventricular weight at necropsy in interstitial pulmonary fibrosis and in chronic bronchitis and emphysema.

The ventricular weights in 43 patients with interstitial pulmonary fibrosis were retrospectively compared with those in 172 patients with emphysema and chronic bronchitis. The mean right ventricular weight of patients with interstitial pulmonary fibrosis and those with emphysema and chronic bronchitis was 85.5 g (SD 23.2) and 88.8 g (34.3), respectively. Thirty five patients (81%) with interstitial pulmonary fibrosis had a right ventricular weight over 65 g compared with 124 (72%) of those with emphysema. Fifty three per cent of both those with interstitial pulmonary fibrosis and those with chronic bronchitis and emphysema had a right ventricular weight greater than 80 g. Differences between the two groups were not significant. These results suggest that the prevalence of right ventricular hypertrophy and pulmonary hypertension in interstitial pulmonary fibrosis is similar to that found in chronic bronchitis and emphysema.

A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillamine use.

A 47 year old man presented with a two year history of increasing cervical dysphagia, dyspnoea, and cutaneous signs. He had been diagnosed 27 years previously with Wilson's disease and was treated with penicillamine (1.5 g daily). Systemic abnormality of elastic fibres was confirmed by light and electron microscopy following biopsy of skin, lung, oesophageal muscle, gum, pharyngeal tissue, and cervical connective tissue. Dysphagia was relieved by cricopharyngeal myotomy. Substitution of trientene dihydrochloride for penicillamine relieved cutaneous and systemic manifestations. This is possibly the first case demonstrating an association between prolonged penicillamine use and biopsy proved systemic pseudo-pseudoxanthoma elasticum. The presenting symptoms may have resulted from the abnormal numbers and properties of elastic fibres, and the changes were caused by penicillamine use, rather than by idiopathic, inherited pseudoxanthoma elasticum.

The effect of ipratropium bromide on maximal exercise capacity in asthmatic and non-asthmatic men.

The effect of 0.5 mg nebulized ipratropium bromide (IB) on the cardio-respiratory responses to a progressive maximal cycle exercise test was compared with a matched placebo (P) in eight mild asthmatic and eight non-asthmatic men. The forced expiratory volume in l s (FEV1) in the asthmatic group was higher after ipratropium bromide both at rest [IB, mean 4.07 (SD 1.18) l versus P, 3.83 (1.29) l, P less than 0.05] and after exercise [IB, 3.64 (1.31) l versus P, 3.30 (1.40) l, P less than 0.02]. Since the percentage fall in the FEV1 after exercise was not significantly changed by ipratropium bromide [IB, -12 (11)% versus P, -16 (14)%], the improvement in the post-exercise FEV1 in the asthmatic group is attributable to the pre-exercise bronchodilatation. The resting and post-exercise FEV1 in the non-asthmatic group were also significantly higher after ipratropium bromide. However, neither group showed any differences in the cardio-respiratory, haemodynamic or subjective responses to the progressive maximum exercise test when ipratropium bromide was compared with placebo. These results demonstrate the absence of significant cardio-respiratory effects during exercise with this relatively high dose of ipratropium bromide, in patients with mild asthma and in non-asthmatic subjects. No ergogenic effect on maximal exercise performance was shown to question its use by asthmatic athletes engaged in high level competition.

Cardio-respiratory responses to exercise following treatment of acute severe asthma.

Asthmatic patients are encouraged to adopt a normal and active life-style. However, following treatment of acute severe asthma, patients may ask for advice about taking exercise. Serial measurements of the cardio-respiratory responses to continuous work load exercise, were made in asthmatic patients convalescing following hospital treatment of an acute exacerbation. Eighteen asymptomatic patients, (seven male) aged 18-48 years, were studied. The first test was performed within 1 week of admission, when the mean (SD) peak expiratory flow rate (PEFR) was 88 (20)% predicted normal and the arterial oxygen tension (PaO2) was 13.1 (1.4) kPa. No significant differences in the mean cardio-respiratory responses, from the last minute of exercise, were found during the 4-week study. There were no significant differences in the four tests, between the resting PEFR, lowest post-exercise PEFR or % change in PEFR. Also, there were no significant differences in the pre-exercise, end of exercise and recovery (10 min after exercise) PaO2, between the four tests. However, taking the four tests as a whole, significant relationships were found between the recovery PaO2 and the lowest post-exercise PEFR, expressed in absolute terms (r = 0.515, P less than 0.001), and as a percentage of predicted normal (r = 0.533, P less than 0.001); and also between the recovery PaO2 and the % change in PEFR after exercise (r = 0.299, P less than 0.05). It is suggested that a formal exercise test should be performed in convalescent asthmatics wishing to participate in active sports. Patients with exercise-induced asthma may then be identified and treated appropriately.

Endurance exercise capacity in adults with cystic fibrosis.

We have compared the maximal and endurance exercise capacities in 22 (15 male) adult cystic fibrosis (CF) patients with a resting oxygen saturation (SaO2) > or = 90%, with age and sex matched controls (CON). The maximum oxygen uptake (VO2max) and heart-rate were lower for the CF group whereas the maximum ventilation reached a higher percentage of predicted. Furthermore, for the CF group there was a relationship between the % predicted VO2max and measures of lung function, confirming a ventilatory limit to maximum exercise in patients with more severe disease and a near normal maximum exercise capacity in those with mild disease. Endurance capacity, defined as the duration of exercise at 80% of each individuals VO2max, was however similar for the two groups [CF: 22.21 (15.82) vs. CON: 24.94 (13.05) min]; despite the CF group exercising under less efficient ventilatory conditions. Endurance capacity was not related to the measurements of lung function. Of the seven CF patients desaturating at maximal exercise (SaO2 < 90%), five desaturated at a work load of 80% VO2max, whereas only one desaturated at 50% VO2max. This study confirms that with increasing severity of disease, maximal exercise capacity may be limited in adult CF patients, whereas endurance capacity (at the same relative work load) is unimpaired. Furthermore, CF patients who desaturate during a progressive maximal exercise test are likely to desaturate during constant work load exercise if the intensity is high but unlikely to do so if the intensity is low. The information from these exercise tests would be of value for prescribing individual training programmes and for evaluating the effects.

The performance of Mini Wright peak flow meters after prolonged use.

The accuracy of 84 new and 35 old Mini Wright peak flow meters were tested using a servo-controlled pump system. The 95% confidence limits for flow measurement across the range of the new meters was between +/- 151 min-1 at the lower end of the range and +/- 28 l min-1 at the top of the range. The readings for 22 (63%) of the old meters (age range 1-13 yr) were within these 95% confidence limits. For the remaining 13 old meters (age range 1-13 yr) whose readings were not within these limits, there were 11 meters with readings falling below and two meters with readings above these limits. Twelve of these old meters were washed and retested and there was no significant change in their readings. Twenty of the new meters were retested after 1 yr of continuous use and their readings were significantly higher with a median value of 5 l min-1 across the range, although only two of these 20 meters had readings outside the 95% confidence limits set from the 84 new meters. It is concluded that whilst Mini Wright meters aged up to 14 yr can give readings which are as good as new meters, some meters demonstrate significant changes in readings after only 1 yr and washing did not correct this change. It is recommended that clinicians prescribing peak expiratory flow (PEF) meters should be responsible for checking the patient's meter as well as their PEF readings at clinic visits.

Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991-1996).

In patients with cystic fibrosis (CF), nasal intermittent positive pressure ventilation (NIPPV) is currently used as a short-term bridge to transplantation but its precise role has yet to be determined. Patients were offered a therapeutic trial of NIPPV when candidates for lung transplantation, with respiratory failure unresponsive to medical treatment. Twelve patients, six male of mean age of 26 +/- 1.4 years, had a trial of NIPPV. At recruitment the mean percentage predicted forced expired volume in one second (FEV1) was 15.1% +/- 1.2%, arterial carbon dioxide (PaCO2) 8.7 +/- 0.6 kPa, arterial oxygen (PaO2) with variable FiO2 7.4 +/- 0.6 kPa and arterial bicarbonate (HCO3-) 40.1 +/- 1.6 mmol l-1. Ten cases tolerated NIPPV for 1-15 months, mean 5.1 +/- 1.4 months, with subjective improvement in headache and quality of sleep. At 3 months, there was significant improvement in forced vital capacity, PaCO2 and arterial HCO3- and there was a reduction in the number of hospital inpatient days (P < 0.05). Subsequently three cases had lung transplantation, four died on the active list and three are awaiting organs. Two patients failed to tolerate NIPPV owing to abdominal bloating and increasing hypercapnia. In conclusion, NIPPV, if tolerated, was a useful adjunct in the treatment of CF patients with hypercapnic respiratory failure awaiting transplantation. Further prospective studies are required to determine the optimum time to commence NIPPV and to clarify its precise role.

The twenty-metre shuttle-running test: a combined test for maximal oxygen uptake and exercise-induced asthma?

A maximal multistage 'twenty-metre shuttle-running test' has already been developed to estimate maximal oxygen uptake (VO2 max). This field test requires little equipment or expertise, can be performed simultaneously by several subjects, and is widely used in physical education lessons. The present study assessed the potential for this test to provoke exercise-induced asthma in 73 schoolboys, aged 15-16 years. Measurements of the forced expiratory volume in one second (FEV1) were made at rest and 10 min after the twenty-metre shuttle-running test; exercise-induced asthma was defined as greater than a 10% fall in FEV1 after exercise. The pupils achieved 73 +/- 19 shuttles (mean +/- SD) giving a VO2 max of 47.0 +/- 5.3 ml kg-1 min-1. Exercise-induced asthma was documented in eight pupils (11%); two were known asthmatics who, despite taking pre-exercise B2 agonist treatment, had sharp falls in FEV1 (-25.4 and -25.6%); two had previously experienced occasional chest tightness or wheeze with exercise (-16.5 and -13.2% fall FEV1); but four were asymptomatic, with no previous asthmatic symptoms (-20.0, -18.2, -15.3 and -11.4% fall FEV1). This study has demonstrated the potential of the twenty-metre shuttle-running test to provoke exercise induced-asthma, and may therefore be a useful clinical test to assess for exercise-induced asthma when an estimate of VO2 max would also be helpful. Furthermore, physical education teachers should take basic precautions when using this test.(ABSTRACT TRUNCATED AT 250 WORDS)

Evaluation of frequency and time-frequency spectral analysis of heart rate variability as a diagnostic marker of the sleep apnoea syndrome.

The sleep apnoea/hypopnoea syndrome (SAHS) elicits a unique heart rate rhythm that may provide the basis for an effective screening tool. The study uses the receiver operator characteristic (ROC) to assess the diagnostic potential of spectral analysis of heart rate variability (HRV) using two methods, the discrete Fourier transform (DFT) and the discrete harmonic wavelet transform (DHWT). These two methods are compared over different sleep stages and spectral frequency bands. The HRV results are subsequently compared with those of the current screening method of oximetry. For both the DFT and the DHWT, the most diagnostically accurate frequency range for HRV spectral power calculations is found to be 0.019-0.036 Hz (denoted by AB2). Using AB2, 15 min sections of non-REM sleep data in 40 subjects produce ROC areas, for the DFT, DHWT and oximetry, of 0.94, 0.97 and 0.67, respectively. In REM sleep, ROC areas are 0.78, 0.79 and 0.71, respectively. In non-REM sleep, spectral analysis of HRV appears to be a significantly better indicator of the SAHS than the current screening method of oximetry, and, in REM sleep, it is comparable with oximetry. The advantage of the DHWT over the DFT is that it produces a greater time resolution and is computationally more efficient. The DHWT does not require the precondition of stationarity or interpolation of raw HRV data.

A double-blind comparison of amoxycillin with trimethoprim in acute exacerbations of chronic bronchitis.

Thirty-seven patients with untreated acute exacerbations of severe chronic bronchitis (mean FEV1 0.81), were entered into a double-blind randomized trial comparing amoxycillin 250 mg three times a day with trimethoprim 200 mg twice a day, each given for seven days. Seventeen patients received amoxycillin, from which there was one treatment failure, and 18 patients received trimethoprim, amongst which there were six treatment failures. There were no major differences between the treatments, in this small group of patients, although a significant difference (in favour of amoxycillin) was demonstrated in the patients' subjective dyspnoea score. Because of the difficulties in collecting sufficient patients from a single centre, the definition of the possible role of trimethoprim alone in the treatment of acute axacerbations of chronic bronchitis may have to await multicentre trials.

Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.

The effect of 5 mg nebulised salbutamol on the cardiorespiratory responses to a progressive maximal exercise test was investigated in eight asthmatic (mean forced expiratory volume in one second (FEV1) 3.48 (1.0) litres) and eight non-asthmatic men. Exercise tests were performed on a bicycle ergometer after administration of nebulised salbutamol or matched saline placebo. In the asthmatic subjects salbutamol increased the resting FEV1 by 11%. The mean (SD) percentage fall in FEV1 after exercise did not change significantly (salbutamol 9.4 (12.8); placebo 15.0 (8.0], but because the FEV1 before exercise was increased the lowest FEV1 after exercise was also significantly higher after salbutamol than placebo (3.60 (1.13) v 2.85 (0.80) litres). Despite the improvement in FEV1 before exercise there was no significant difference in maximal workload, oxygen uptake, heart rate, or ventilation during exercise after salbutamol compared with placebo in the asthmatic patients. Tidal volume was higher at maximal exercise after salbutamol but there was no change in perception of breathlessness or exertion in the asthmatic subjects. During submaximal progressive exercise the perceived rate of exertion was reduced in the asthmatic patients and oxygen pulse was reduced in both groups owing to a small and non-significant increase in heart rate. The FEV1 and cardiorespiratory response to the progressive maximal exercise test in the non-asthmatic subjects were otherwise unchanged after salbutamol. The results suggest that 5 mg nebulised salbutamol has little effect on the cardiorespiratory responses to progressive maximal exercise in patients with mild asthma and in non-asthmatic subjects. Salbutamol in this dose may reduce the severity of exercise induced asthma, but no ergogenic effect on maximal exercise performance was shown.

Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome.

Formulating a rational health policy necessitates the ability to compare between different healthcare interventions and disease scenarios. Continuous positive airway pressure (CPAP) therapy with a conservative lifestyle strategy in sleep apnoea/hypopnoea syndrome (SAHS) was evaluated using health utility and quality-adjusted life years (QALYs) as outcome measures. A total 71 SAHS (apnoea/hypopnoea index > or = 15 h(-1)) patients completed a randomised, parallel group study over 3 months using utilities derived by the standard gamble approach (Usg) and European quality of life questionnaire (Euroqol) (Ueq). The severely impaired health status at baseline improved by 23% (Usg 0.32 to 0.55) adding 8 QALYs in the CPAP group, compared to a 4% improvement with 4.7 QALYs added in the lifestyle group (Usg 0.31 to 0.35). The Ueq showed a marginal change with CPAP (0.73 to 0.77) but did not demonstrate any improvement with lifestyle intervention. The health status impairment in sleep apnoea/hypopnoea syndrome patients is markedly improved by continuous positive airway pressure compared to a modest improvement with conservative lifestyle strategies using the standard gamble utility, which may be incorporated in effectiveness and economic analyses. The European quality of life questionnaire did not reflect a similar degree of impact and is probably not useful in this population.

Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma.

Topical steroid therapy is now widely used in the treatment of chronic asthma, but few controlled studies have been conducted to evaluate the most efficient dosage regimen. The present study was designed to assess, in a double-blind fashion, the relative efficacy of a new topical steroid, budesonide (Pulmicort) in controlling pulmonary function and asthma symptoms during twice-and 4-times daily dosing. Both active and placebo drug were administered via the tube spacer inhaler. Objective lung function measurements indicate that twice-daily dosing is at least as effective as 4-times daily dosing, and it is suggested that the twice-daily dosage regimen may lead to better patient compliance.

Triamcinolone in corticosteroid-resistant asthma.

In an uncontrolled study 38 patients with chronic asthma were treated for up to 4.5 years (mean 2.9) with depot injections of triamcinolone acetonide. About half had proved difficult to control on large doses of corticosteroid tablets. Three-quarters were helped and the incidence of hospital admission amongst them was reduced. Side effects were tolerable and adrenal function was only moderately depressed. Spirometry showed continuing improvement up to three years after starting triamcinolone. Whether similar improvement could have been achieved by a different dosage regimen of corticosteroid tablets or whether it might have ocurred spontaneously was not tested. A controlled trial seems warranted.

Combined index of heart rate variability and oximetry in screening for the sleep apnoea/hypopnoea syndrome.

Many sleep centres employ a preliminary screening test in order to reduce the number of polysomnographies required in the routine diagnosis of the sleep apnoea/hypopnoea syndrome (SAHS). We investigated the combination of heart rate and oximetry information as a means of performing this test. A retrospective study of 100 patients with suspected SAHS was made. All patients had in-hospital polysomnography on one night. We estimated the number of respiratory event-related arousals by counting the number of autonomic arousals (assessed on the basis of changes in the heart interbeat interval) that were coincident with a rise in oximetry. The hourly index of such events was denoted the "cardiac-oximetry disturbance index" (CODI). The median apnoea/hypopnoea index (AHI) was 16.5 (range 1.0-93.6) h-1. The CODI correlated significantly with the AHI (Spearman correlation coefficient rs = 0.88, P < 0.01), and the area (+/- standard error) under the receiver operating characteristic (ROC) was 0.94 +/- 0.05. Oximetry alone (based on 4% dips) was a less effective screening test (rs = 0.80, P < 0.01; area under ROC 0.83 +/- 0.06). Using 2% dips in oximetry offered comparable performance with the CODI (rs = 0.91, P < 0.01; area under ROC 0.93 +/- 0.04). The CODI was better correlated with the electroencephalograph arousal index (rs = 0.84, P < 0.01) than was oximetry (2% dips, rs = 0.57, P < 0.01). The CODI algorithm also offers an informal measure of self-validation: a large discrepancy between the number of autonomic arousals and the number of rises in oximetry indicates the presence of autonomic arousals without changes in oximetry (or vice versa). This self-validation mechanism identified several patients in this study, and may be useful in identifying sleep disruption due to chronic pain or other causes.